Business Context and Reporting Period
This Form 8-K Current Report was filed by Oragenics, Inc. (d/b/a ONI BioPharma, Inc.) on June 27, 2008. The filing reports on executive leadership changes effective in late June and mid-July 2008.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements.
Material Changes
- Executive Appointments: David Hirsch was appointed Chief Operating Officer (effective June 27, 2008) and Chief Financial Officer (effective July 15, 2008).
- Executive Departure: Dotti Delfino is retiring as Chief Financial Officer on July 15, 2008. She will remain as a consultant until July 2009 to assist with the transition.
- Compensation Structure: Mr. Hirsch's compensation includes a base salary of at least $150,000, potential bonuses up to 40% (discretionary up to 100%), and a stock option award of 500,000 shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. Specific contingencies related to Mr. Hirsch's employment include:
- Stock Vesting: 66,667 options vested immediately. The remaining 433,333 options vest upon the company's stock price reaching specific thresholds ($1.00, $2.00, $3.00, and $5.00 per share).
- Severance: In the event of termination without cause or for good reason, Mr. Hirsch is eligible for 9 months of base salary. If terminated within six months of an unapproved change in control, severance increases to 24 months of base salary.
Investor Verification Checklist
- Verify the current stock price to determine the vesting status of Mr. Hirsch's 433,333 performance-based stock options.
- Confirm the transition timeline for the CFO role between Dotti Delfino and David Hirsch through July 15, 2008.
- Review the attached press release (Exhibit 99.1) for additional details on the retirement of Ms. Delfino.
- Monitor future filings for the impact of the new CFO on financial reporting and liquidity management.